Printer Friendly

IDB EXTENDS RESEARCH COLLABORATIONS WITH NEW ENGLAND DEACONESS HOSPITAL AND BIOMERIEUX VITEK.

VANCOUVER--(BUSINESS WIRE)--Feb. 9, 1995-- ID Biomedical Corporation (IDB) announced today that it has extended for an additional nine months its collaborative research agreement with New England Deaconess Hospital, a major teaching hospital of Harvard Medical School. The collaboration relates to the development of a direct HIV test using IDB's Cycling Probe Technology (CPT).

"The collaboration has produced very encouraging results in that a specific diagnostic probe sequence for HIV and a unique approach to clinical sample preparation have been verified," stated Dr. Peter Duck, Vice President of Research for IDB. "Subsequent work will now focus on extending these preliminary results to clinical samples and on target quantification."

Dr. David Scadden, lead investigator of the collaboration at Deaconess stated that he is "very excited by the preliminary results" and is "pleased to be developing an assay with such a powerful potential for HIV quantification."

In another collaboration involving an infectious disease, IDB and bioMerieux Vitek, Inc. have agreed to extend their research agreement until March 31, 1995. Positive preliminary results have supported additional work and the extension of the collaboration.

Directly and through its collaborations, IDB's research programs for CPT now include tests for seven infectious diseases, a cancer diagnostic and a genetic disease.

ID Biomedical Corporation is a Canadian biotechnology company which is developing a nucleic acid diagnostic system and related products based on its proprietary SLT and CPT technologies. The Company, through its subsidiary ID Vaccine Corporation, is also developing a subunit vaccine against tuberculosis.

Neither NASDAQ, The Montreal Exchange nor the Vancouver Stock Exchange has approved or disapproved of the information contained herein.

CONTACT: ID Biomedical Corp.

Hugh Notman, Director, Corporate Communications or

Dr. Anthony Holler, Medical Director, 604/431-9314
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 9, 1995
Words:284
Previous Article:Columbus Realty Trust announced credit facility modification.
Next Article:Danka Business Systems files preliminary proxy materials with the SEC.
Topics:


Related Articles
Sex and the risk of heart attack.
Boston Health Care International.
TI OPENS INFORMATION APPLIANCE DESIGN CENTER IN TAIWAN.
J. Richard Gaintner. (Members on the Move).
Emergence of vancomycin-intermediate staphylococcus aureus and S. sciuri, Greece. (Letters).
The business of education: a new paradigm.
Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters